Canaccord Genuity Starts Blueprint Medicines (BPMC) at Buy
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Canaccord Genuity initiated coverage on Blueprint Medicines (NASDAQ: BPMC) with a Buy rating and a price target of $26.00.
Shares of Blueprint Medicines closed at $21.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Genuity Remains Bullish on Intel (INTC)
- Abraxas Petroleum (AXAS) Prices 25M Share Upsized Offering at $2.40
- Skyworks Solutions (SWKS) PT Raised to $96 at Canaccord Genuity
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesCanaccord Genuity
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!